Dr. Rupal Trivedi, MD
Family Medicine (Family Medicine Physician)
At a glance
- In the NPI registry since
- 2007
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
MO license 2011019884
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 1 companies reported 2 payments worth $64.54 in total to this clinician.
| Novo Nordisk Inc | $64.54 |
|---|
| Education | $64.54 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novo Nordisk Inc Jul 21, 2025 | Education in-kind | $32.27 |
| Novo Nordisk Inc Jul 21, 2025 | Education in-kind | $32.27 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 18 industry-funded studies in 2025, from 7 companies. The companies reported $2,515,644 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are…
Amgen Inc. - Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults
Valneva Austria GmbH · Completed · NCT06334393 - BNT163-01
BioNTech SE - A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age
ModernaTX, Inc. · Terminated · NCT05701800 - A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
ModernaTX, Inc. · Completed · NCT06602024 - A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Me…
Amgen Inc. - A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
Eli Lilly and Company · Completed · NCT06230523 - Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy
Eli Lilly and Company · Status unknown · NCT02968303 - A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight
Eli Lilly and Company · Completed · NCT06683508 - A phase 1 double-blind, randomized, dose-finding clinical trial with an open-label run-in part to assess the safety and immunogenicity of an inactivated, adjuvanted whole zika virus vaccine candidate (VLA1601) in heal…
Valneva Austria GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.